How Modern Telehealth Platforms Earn Revenue

Scale & Growth

Apr 16, 2026

Daniel Meursing

7 Mins Read Time

How Modern Telehealth Platforms Build Revenue at Scale

TLDR

TLDR The telemedicine market reached $114.98 billion in 2023 and is projected to grow at a 17.96% CAGR through 2030.[1] Telehealth is not a single business model — it is a category with radically different approaches to revenue, delivery, and scale. Understanding which model fits your goals is the difference between a sustainable platform and an expensive compliance project. ⚠ Disclaimer: This article is for informational purposes only. It does not constitute medical, legal, or financial advice. Consult qualified professionals before launching any health program or business.

The Five Core Telehealth Business Models

Every telehealth business ultimately falls into one of five revenue architectures. Knowing which one you are building before you spend on infrastructure, saves months and capital.

Direct-to-Consumer Subscription: Patients pay a monthly or quarterly fee for ongoing access to clinical review, prescriptions, and medication delivery. This is the dominant structure in prescription wellness, weight management, hormone therapy, peptide programs. Revenue is predictable, LTV is compoundable, and acquisition cost amortizes across many billing cycles rather than a single transaction.

Pay-Per-Consultation: Patients pay per individual visit with no recurring commitment. Works for acute care or episodic conditions but produces volatile revenue. Each patient requires a fresh acquisition trigger for every billing event, making CAC economics difficult to sustain without high visit frequency.

Employer and B2B: Telehealth access is bundled into employee benefits packages or sold to enterprise wellness programs. Contracts deliver stable revenue but involve longer sales cycles, volume commitments, and institutional procurement processes. Better suited to operators with existing enterprise relationships than to brand-first DTC operators.

Insurance Integrated: Providers bill insurance payers for reimbursable telehealth visits. Requires provider credentialing, billing infrastructure, payer contracting, and claims processing overhead. High per-visit revenue but significant administrative load — unsuitable for most non-clinical operators entering telehealth from a brand or wellness angle.

White Label Platform as a Service: Non-clinical operators license a turnkey clinical infrastructure stack — licensed providers, pharmacy integrations, HIPAA compliance, and prescribing workflows — and operate it under their own brand. The operator contributes audience trust and acquisition. The platform provides everything clinical. This is the fastest and lowest-capital-requirement path for brand operators entering prescription wellness.

The Five Core Telehealth Business Models

Why the DTC Subscription Model Dominates

The real innovation of DTC telehealth platforms like Hims and Hers is not telemedicine — it is the conversion of episodic clinical needs into a subscription revenue stream. That architectural decision produces three compounding economic advantages that pay-per-visit models structurally cannot replicate.

Predictable cash flow. Monthly recurring revenue from an active subscriber base smooths the revenue volatility that destroys DTC health businesses relying on seasonal or impulse purchase patterns. Forecasting, staffing, and capital allocation all improve with MRR visibility.

Lower patient acquisition cost amortization. A $100 CAC against a $99/month subscription with 10-month average retention produces $990 in gross revenue per patient acquired — an LTV:CAC ratio of nearly 10:1. The same $100 CAC against a single $99 visit produces a ratio of approximately 1:1. The subscription changes the entire acquisition math.

Clinical relationship continuity. Patients enrolled in ongoing programs — weight management, hormone optimization — achieve better outcomes than those in episodic care precisely because the clinical relationship persists. Better outcomes reduce voluntary churn. Reduced churn compounds LTV further. The clinical and business incentives align.

Hims & Hers reported over 2 million subscribers in their most recent annual report, with subscriber LTV driving the majority of their recognized revenue.[2] The subscription model is not a trend. It is the architecture that makes DTC telehealth defensible.

Why the DTC Subscription Model Dominates

The Unit Economics of a Telehealth Business

A telehealth business at 1,000 active patients paying $150/month generates $150,000 in gross monthly revenue. Whether that revenue produces a profitable business depends entirely on the cost structure underneath it.

In a manually operated clinic model, the cost components compound quickly: licensed provider payroll or 1099 costs (typically $60–$90/hour for NPs), malpractice insurance ($5,000–$20,000/year per provider), pharmacy coordination labor, HIPAA compliance infrastructure, credentialing overhead, and customer support. These costs carry as fixed or semi-fixed charges regardless of patient volume fluctuations — meaning a bad acquisition month still produces full cost exposure.

In a white label platform model, these layers shift from fixed costs the operator builds to variable costs embedded in the platform fee structure. The operator pays a percentage of revenue or a per-patient fee. When volume drops, platform costs drop proportionally. When volume grows, clinical infrastructure scales automatically without operator-managed hiring.

The practical result: white label operators typically reach contribution margin positivity at lower patient volumes than clinic-build operators, because the breakeven threshold is not anchored to a fixed clinical overhead base.

For operators modeling this decision, the calculation requires mapping: cost per patient acquisition, expected monthly subscription value, estimated average retention (months), and platform cost per active patient. The economics favor platform models most strongly in the 100–5,000 active patient range — before custom infrastructure investment begins to amortize

How White Label Telehealth Changes the Economics

White label telehealth platforms restructure the P&L of a clinical operator in ways that a clinic-build model cannot match at early stage.

The licensed providers, pharmacy integrations, HIPAA-compliant workflows, and prescribing infrastructure are provided by the platform as part of its operating model. The operator earns margin on patient program revenue without carrying the clinical cost structure underneath it.

This does not mean white label is always the right model for every operator. Operators with unique clinical differentiation, existing provider networks, or technical requirements no platform covers may find custom infrastructure worthwhile over a longer time horizon. But for brand-first operators — wellness brands, med spas, fitness platforms, e-commerce businesses — entering telehealth for the first time, the white label model typically produces:

Revenue start within weeks rather than 12–18 months
Compliance infrastructure from day one rather than built in parallel to operations
Clinical overhead that scales with revenue rather than against it
No provider credentialing, malpractice management, or pharmacy contract negotiation

FUSE Health is built specifically for this operator category — providing the complete clinical stack as infrastructure that non-clinical brands configure and deploy under their own brand.

Which Telehealth Business Model Is Right for You

The right model depends on what you bring into the market and what your revenue timeline requires.

If you are a licensed clinical operator with existing patients, provider relationships, and credentialing already established, an insurance-integrated or hybrid model maximizes per-visit revenue and builds on infrastructure you already carry.

If you are an employer or HR platform, the B2B benefits model offers stable contract revenue with predictable renewal cycles — assuming you have the sales infrastructure and patience for enterprise procurement timelines.

If you are a wellness brand, fitness company, supplement business, or any DTC consumer brand with an existing audience and no clinical infrastructure, the white label subscription model delivers the best risk-adjusted return. You own the patient relationship. You set pricing. You earn margin on clinical program revenue. You do not hire providers, negotiate pharmacy contracts, or build HIPAA infrastructure.

The evaluation framework is straightforward: How much capital do you have before you need revenue? How long can you sustain a pre-revenue build? What clinical differentiation, if any, do you need that no existing platform provides? If the answer to that last question is "none," the platform model is almost always the right answer for brand operators in 2026.

Which Telehealth Business Model Is Right for You

Conclusion

The telehealth business model landscape is consolidating around operators who chose the right infrastructure architecture before they spent on patient acquisition. Compliance shortcuts, custom builds without clinical differentiation, and manual workflows that break at volume — these are the structural decisions that determine which operators scale and which ones rebuild.

For non-clinical brand operators, the white label subscription model is the fastest and most capital-efficient path to a defensible telehealth revenue stream. FUSE Health provides the complete clinical infrastructure to launch that model — licensed providers, pharmacy integrations, HIPAA compliance, and subscription management — in a platform that scales with your program rather than against it.

Daniel Meursing

CEO

Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he leads FuseHealth, enabling healthtech companies to build compliant, scalable patient programs.

Background

Startup Operations & Service Systems

Experience

2x Founder, Multi-Market U.S. Scaling

Qualifications

Healthtech Infrastructure & Patient Access

Key Achievement

Scaled Premier Staff & Eventstaff across major U.S. markets

References

[1] Grand View Research, "Telemedicine Market Size & Share Report," 2024. grandviewresearch.com

[2] Hims & Hers Health, Inc., Annual Report (Form 10-K), FY 2024. SEC EDGAR, sec.gov

[3] McKinsey & Company, "Telehealth: A quarter-trillion-dollar post-COVID-19 reality?" Consumer Health Survey, 2024.

⚠ Medical & Legal Disclaimer

This article is for informational purposes only and does not constitute medical advice, legal advice, or a guarantee of clinical or financial outcomes. All telehealth programs should be developed in consultation with qualified legal and clinical professionals. Revenue projections referenced are illustrative and not guarantees of financial performance. Regulatory requirements change — verify current requirements with qualified counsel before launch.